Health NZ welcomes Roche’s offer of an Early Access Programme for people with unresectable hepatocellular carcinoma
Health NZ is pleased to accept an offer from Roche to provide two medicines for people with unresectable hepatocellular carcinoma until the end of February. The medicines, Tecentriq (atezolizumab) and Avastin (bevacizumab) will be available free of charge as part of a bridging programme while Pharmac carries out consultation for funding bevacizumab (Vegzelma) and widening ...